

MOTION SICKNESS RELIEF- dimenhydrinate tablet
L.N.K. International, Inc.

Quality Plus 44-198

Active ingredient (in each tablet)

Dimenhydrinate 50 mg

Purpose

Antiemetic

Uses

for prevention and treatment of these symptoms associated with motion sickness:

- nausea
- vomiting
- dizziness

Warnings

Do not use

for children under 2 years of age unless directed by a doctor.

Ask a doctor before use if you have

- a breathing problem such as emphysema or chronic bronchitis
- glaucoma
- difficulty in urination due to enlargement of the prostate gland

Ask a doctor or pharmacist before use if you are

taking sedatives or tranquilizers.

When using this product

- marked drowsiness may occur
- avoid alcoholic beverages
- alcohol, sedatives, and tranquilizers may increase drowsiness
- use caution when driving a motor vehicle or operating machinery

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

- to prevent motion sickness, the first dose should be taken one-half to one hour before starting activity

| | |
|---------------------------------------|---|
| adults and children 12 years and over | 1 to 2 tablets every 4-6 hours; do not exceed 8 tablets in 24 hours, or as directed by a doctor |
| children 6 to under 12 years | ½ to 1 tablet every 6-8 hours; do not exceed 3 tablets in 24 hours, or as directed by a doctor |
| children 2 to under 6 years | ½ tablet every 6-8 hours; do not exceed 1½ tablets in 24 hours, or as directed by a doctor |

Other information

- **each tablet contains:** calcium 35 mg
- see end flap for expiration date and lot number
- **TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN**
- store at 25°C (77°F); excursions permitted between 15°C-30°C (59°F-86°F)
- protect from moisture

Inactive ingredients

croscarmellose sodium, dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, stearic acid

Questions or comments?

1-800-426-9391

Principal display panel

**QUALITY
+PLUS**

NDC 50844-199-02

*Compare to active ingredient in
Dramamine® Original Formula

ORIGINAL FORMULA

Motion Sickness Relief

Dimenhydrinate 50 mg • Antiemetic

PREVENTS NAUSEA,
VOMITING & DIZZINESS
FOR CHILDREN & ADULTS

**12
Tablets**

ACTUAL
SIZE

*This product is not manufactured or distributed by Medtech Products Inc., owner of the registered trademark Dramamine® Original Formula.

TAMPER EVIDENT: DO NOT USE IF PACKAGE IS OPENED OR IF BLISTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING

50844 REV0518B19802

Distributed by **LNK INTERNATIONAL, INC.**
60 Arkay Drive
Hauppauge, NY 11788
USA

No Print/No Varnish
Lot & Exp Date

3 50844 19902 7

QUALITY PLUS

ORIGINAL FORMULA

Motion Sickness Relief

Dimenhydrinate 50 mg • Antiemetic

12 Tablets

PREVENTS NAUSEA, VOMITING & DIZZINESS FOR CHILDREN & ADULTS

ACTUAL SIZE



NDC 50844-199-02

*Compare to active ingredient in Dramamine® Original Formula

Drug Facts (continued)

Warnings

Do not use for children under 2 years of age unless directed by a doctor.

nausea ■ vomiting ■ dizziness

Drug Facts (continued)

Drug Facts (continued)

Active ingredient (in each tablet)

Dimenhydrinate 50 mg - Antiemetic

Purpose

Uses for prevention and treatment of these symptoms associated with motion sickness:

Drug Facts (continued)

Drug Facts (continued)

Warnings

TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BUSTERS ARE TORN OR BROKEN

store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F) ■ protect from moisture

■ protect from moisture

Drug Facts (continued)

Drug Facts (continued)

Directions

to prevent motion sickness, the first dose should be taken one-half to one hour before starting activity.

adults and children 12 years and over: 1 to 2 tablets every 4-6 hours, do not exceed 8 tablets in 24 hours, or as directed by a doctor.

children 6 to under 12 years: ½ to 1 tablet every 6-8 hours, do not exceed 3 tablets in 24 hours, or as directed by a doctor.

children 2 to under 6 years: ½ tablet every 6-8 hours, do not exceed 1½ tablets in 24 hours, or as directed by a doctor.

Other information

each tablet contains: calcium 35 mg

see end flap for expiration date and lot number

Drug Facts (continued)

Drug Facts (continued)

Warnings

Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis ■ glaucoma ■ difficulty in urination due to enlargement of the prostate gland

Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers.

When using this product

marked drowsiness may occur ■ avoid alcoholic beverages ■ alcohol, sedatives, and tranquilizers may increase drowsiness ■ use caution when driving a motor vehicle or operating machinery

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Drug Facts (continued)

Drug Facts (continued)

Questions or comments? 1-800-426-9391

dicbas calcium phosphate dhydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, stearic acid

Drug Facts (continued)

Drug Facts (continued)

Warnings

This product is not manufactured or distributed by Medtech Products Inc., owner of the registered trademark Dramamine® Original Formula.

Drug Facts (continued)

Drug Facts (continued)

Warnings

TAMPER EVIDENT: DO NOT USE IF PACKAGE IS OPENED OR IF BUSTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING

50844 REV0518B19802

Distributed by LNK INTERNATIONAL, INC.
60 Arkay Drive
Hauppauge, NY 11788
USA

Quality Plus 44-198

MOTION SICKNESS RELIEF

dimenhydrinate tablet

Product Information

| | | | |
|--------------------------------|----------------|---------------------------|---------------|
| Product Type | HUMAN OTC DRUG | Item Code (Source) | NDC:50844-199 |
| Route of Administration | ORAL | | |

Active Ingredient/Active Moiety

| Ingredient Name | Basis of Strength | Strength |
|-----------------|-------------------|----------|
|-----------------|-------------------|----------|

| | | |
|--|-----------------------|-------|
| DIMENHYDRINATE (UNII: JB937PER5C) (DIPHENHYDRAMINE - UNII:8GTS82S83M, 8-CHLOROTHEOPHYLLINE - UNII:GE2UA340FM) | DIMENHYDRINATE | 50 mg |
|--|-----------------------|-------|

Inactive Ingredients

| Ingredient Name | Strength |
|---|----------|
| CROSCARMELOSE SODIUM (UNII: M28OL1HH48) | |
| DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP) | |
| MAGNESIUM STEARATE (UNII: 70097M6I30) | |
| MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) | |
| SILICON DIOXIDE (UNII: ETJ7Z6XBU4) | |
| STEARIC ACID (UNII: 4ELV7Z65AP) | |

Product Characteristics

| | | | |
|-----------------|-------|---------------------|----------|
| Color | white | Score | 2 pieces |
| Shape | ROUND | Size | 9mm |
| Flavor | | Imprint Code | 44;198 |
| Contains | | | |

Packaging

| # | Item Code | Package Description | Marketing Start Date | Marketing End Date |
|---|------------------|--|----------------------|--------------------|
| 1 | NDC:50844-199-02 | 2 in 1 CARTON | 12/01/1992 | |
| 1 | | 6 in 1 BLISTER PACK; Type 0: Not a Combination Product | | |

Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------|--|----------------------|--------------------|
| OTC Monograph Drug | M009 | 12/01/1992 | |

Labeler - L.N.K. International, Inc. (038154464)

Establishment

| Name | Address | ID/FEI | Business Operations |
|-------------------------|---------|-----------|---------------------|
| LNK International, Inc. | | 038154464 | pack(50844-199) |

Establishment

| Name | Address | ID/FEI | Business Operations |
|-------------------------|---------|-----------|--|
| LNK International, Inc. | | 832867837 | manufacture(50844-199) , pack(50844-199) |

Establishment

| Name | Address | ID/FEI | Business Operations |
|------|---------|--------|---------------------|
|------|---------|--------|---------------------|

Revised: 6/2025

L.N.K. International, Inc.